Sinorda Pharmaceutical attends the 4th DJSeedin Innovation & Collaboration Summit

On May 15, 2024, the 4th DJSeedin Innovation & Collaboration Summit was successfully held in Shanghai, drawing together numerous experts and industry representatives from the global biopharmaceutical sector. Professor Hu Pingsheng, Chairman of Sinorda Pharma, attended the conference on behalf of the company and presented its pipeline projects and strategic development plans, garnering significant attention.

Sinorda Pharmaceutical Pipeline

SND001 Linagliptin Ester (X842)

SND001 linaclotide ester (X842) is a next-generation acid-suppressing drug belonging to the class of potassium-ion competitive acid blockers (P-CABs). Compared to traditional proton pump inhibitors (PPIs), it boasts rapid onset, long-lasting effects, and reversible inhibition of the H⁺,K⁺-ATPase enzyme. It is indicated for the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Helicobacter pylori (H. pylori) infection. Currently, SND001 has been submitted for New Drug Application (NDA) review by the National Medical Products Administration.

SND002 Sentinel Lymph Node T-cell Antitumor Drug

SND002, a tumor-targeting T-cell drug derived from sentinel lymph nodes (Sentinel Lymph Node T Cell, SLN-T), has received approval from the European Union for its Phase II clinical trial. It was also approved in 2013 as part of China’s National Key Science and Technology Project focused on "Major New Drug Development." SLN-T is an individualized cell therapy tailored specifically to target tumors. Early results from multi-center exploratory clinical trials indicate that this T-cell vaccine can significantly improve survival rates among patients with stage IV colorectal cancer.

SND006 Bispecific Antibody Drug

SND006 is an internationally leading bispecific antibody drug for autoimmune diseases currently being developed by Sinorda Pharma, with inflammatory bowel disease (IBD) as its first targeted indication. SND006 features a novel target combination, demonstrating broad potential applicability and high commercial value, and is poised to achieve breakthroughs in the treatment of various autoimmune disorders.